Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A New Type of Investor Relations for Biopharma

This article was originally published in RPM Report

Executive Summary

The biopharma industry is facing strong pressure to justify its pricing practices. And not just from politicians.

You may also be interested in...



When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street

Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.

Washington Threatens; Wall Street Reacts

The biotech investment boom hit the brakes at the end of the first quarter when Rep. Henry Waxman (D-Calif.) publicly complained about Gilead’s pricing for the hepatitis C therapy Sovaldi. The fact that Waxman’s attack has little substantive impact didn’t seem to matter. Another Washington threat—to undo “tax inversion” strategies—is probably much more real, but may actually boost the sector for the rest of 2014.

The Real ‘Pill Penalty’: US Biosimilar Law, Not The IRA

Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel